IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:		Docket No.:	4115-194
Applicants:	PAUZA, C. David, et al.)) Conf. No.:)	7524
Application No.:	10/539,677) Art Unit:	1648
Date Filed:	September 6, 2005	Examiner:	Louise Humphrey, PhD
Title:	VACCINES AGAINST HIV-1 TAT PROTEIN TO GENERATE NEUTRALIZING ANTIBODIES	Customer No.: Customer No.:	23448

CERTIFICATE OF EFS FILING

I hereby certify that this document is being filed via EFS in the United States Patent and Trademark Office on February 5, 2008. /Steven J. Hultquist/

RESPONSE TO JANUARY 8, 2008 RESTRICTION REQUIREMENT IN U.S. PATENT APPLICATION NO. 10/539,677

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

This responds to the January 8, 2008 Office Action in the above-identified application.

In the January 8, 2008 Office Action, the Examiner has required restriction under the provisions of 35 U.S.C. 121 between:

4115-194

• Group I claims 3-11, drawn to a therapeutic composition comprising at least one peptide

having an amino sequence selected from SEQ ID NO: 1-6;

• Group II claims 12-16, drawn to a method of inducing production of neutralizing Tat

antibodies that inhibit internalization of Tat into T-cell;

• Group III claims 22-28 drawn to a polynucleotide sequence encoding at least about 15 to

about 21 amino residues from the amino terminus region of HIV Tat; and an expression

vector comprising the polynucleotide;

• Group IV claims 32 drawn to a method of expressing a Tat amino terminus linear epitope

peptide using the polynucleotide sequence encoding at least about 15 to about 21 amino

acid residues from the amino acid residues from the amino terminus region of HIV Tat;

• Group V claim 37 drawn to the special technical feature of an antibody immunoreactive

with a Tat amino terminus linear epitope; and

Group VI claim 40 drawn to a method of producing an antibody that is immunoreactive

with a Tat amino terminus linear epitope peptide.

In response, applicants hereby elect Group I claims 3-11.

Such election is hereby made with the request that upon finding of allowable subject matter in

the elected Group I claims, the non-elected method claims of Groups II, IV and VI be rejoined

with the Group I claims, under the provisions of MPEP 821.04.

The January 8, 2008 Office Action also contains a species election requirement, between the

following species of carrier proteins:

(1) Gag or fragments thereof;

(2) Env or fragments thereof;

(3) Nef or fragments thereof; and

(4) ovalbumin.

In response, applicants hereby elect Gag or fragments thereof.

The elected claims readable on such species are claims 3-11.

2

It is requested that the examination of this application proceed, consistent with the foregoing elections.

Respectfully submitted,

/steven j. hultquist/

Steven J. Hultquist Reg. No. 28,021 Attorney for Applicants

INTELLECTUAL PROPERTY/ TECHNOLOGY LAW Phone: (919) 419-9350 Fax: (919) 419-9354

Attorney File No.: 4115-194

The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 08-3284